NEPH - Nephros Inc Stock Price, Fair Value and News

2.38USD+0.11 (+4.85%)Market Closed

Market Summary

USD2.38+0.11

Market Closed

4.85%

NEPH Stock Price

View Fullscreen

NEPH RSI Chart

NEPH Valuation

Market Cap

25.1M

Price/Earnings (Trailing)

-17.45

Price/Sales (Trailing)

1.76

EV/EBITDA

-4.54

Price/Free Cashflow

-112.53

NEPH Price/Sales (Trailing)

NEPH Profitability

EBT Margin

-31.79%

Return on Equity

-17.58%

Return on Assets

-12.6%

Free Cashflow Yield

-0.89%

NEPH Fundamentals

NEPH Revenue

Revenue (TTM)

14.2M

Rev. Growth (Yr)

-4.73%

Rev. Growth (Qtr)

-2.42%

NEPH Earnings

Earnings (TTM)

-1.4M

Earnings Growth (Yr)

44.77%

Earnings Growth (Qtr)

74.16%

Breaking Down NEPH Revenue

Last 7 days

13.3%

Last 30 days

19.6%

Last 90 days

-32.2%

Trailing 12 Months

88.9%

How does NEPH drawdown profile look like?

NEPH Financial Health

Current Ratio

4.21

NEPH Investor Care

Shares Dilution (1Y)

0.56%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	11.5M	0	0	14.2M
2022	9.7M	10.3M	10.2M	10.0M
2021	8.8M	9.5M	9.9M	10.3M
2020	0	0	0	8.6M
2018	0	0	0	0
2017	2.5M	2.8M	3.3M	0
2016	2.0M	1.9M	2.1M	2.3M
2015	1.8M	1.9M	1.8M	1.9M
2014	1.7M	1.6M	1.6M	1.7M
2013	1.8M	2.1M	1.9M	1.7M
2012	2.1M	1.7M	1.9M	1.8M
2011	2.6M	2.5M	2.2M	2.2M
2010	0	2.8M	2.8M	2.9M
2009	0	0	0	2.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nephros Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	wexford capital lp	sold	-	-	-91,463	-
Mar 13, 2024	amron arthur h	acquired	-	-	91,463	-
Mar 12, 2024	amron arthur h	bought	17,129	2.4471	7,000	-
Dec 13, 2023	amron arthur h	acquired	-	-	9,291	-
Dec 13, 2023	spandow oliver j.	acquired	-	-	14,294	-
Dec 13, 2023	lask alisa	acquired	-	-	9,291	-
Dec 13, 2023	harris joseph michael	acquired	-	-	9,291	-
Dec 07, 2023	banks robert r. jr.	bought	39,646	2.2026	18,000	president and ceo
Aug 15, 2023	banks robert r. jr.	bought	3,206	1.6869	1,901	president and ceo
Aug 14, 2023	banks robert r. jr.	bought	148	1.5	99.00	president and ceo

Which funds bought or sold NEPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	ELKHORN PARTNERS LIMITED PARTNERSHIP	added	12.85	-31,000	79,000	0.06%
May 15, 2024	STATE STREET CORP	unchanged	-	-19,779	34,379	-%
May 15, 2024	MORGAN STANLEY	reduced	-83.94	-104,982	11,876	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-28.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	76.46	1,009	9,638	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	25,441	25,441	-%
May 15, 2024	WEXFORD CAPITAL LP	reduced	-2.23	-4,796,720	7,945,510	1.62%
May 14, 2024	NewEdge Advisors, LLC	new	-	78.00	78.00	-%
May 13, 2024	BARD ASSOCIATES INC	reduced	-4.24	-255,287	392,834	0.14%
May 13, 2024	UBS Group AG	added	2,690	634	672	-%

Are Funds Buying or Selling NEPH?

Are funds buying NEPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NEPH

No. of Funds

Unveiling Nephros Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 03, 2023	cowen prime advisors llc	-	0	SC 13G
Feb 03, 2023	cowen prime advisors llc	-	0	SC 13G
Feb 03, 2023	cowen prime advisors llc	4.00%	1,431,404	SC 13G
Jan 06, 2023	intelligent fanatics capital management llc	0%	0	SC 13G/A
Feb 28, 2022	intelligent fanatics capital management llc	5.12%	525,408	SC 13G
Feb 09, 2022	cowen prime advisors llc	6%	633,050	SC 13G
Feb 08, 2022	samjo capital llc	4.2%	425,000	SC 13G/A
Jun 11, 2021	evans daron	4.7%	478,874	SC 13D/A
Jan 27, 2021	cowen prime services llc	6%	575,077	SC 13G
Oct 26, 2020	wexford capital lp	36.78%	6,664	SC 13D/A

Recent SEC filings of Nephros Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 10, 2024	S-3	S-3
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 12, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Nephros Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Nephros Inc News

Latest updates

Nephros Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	-2.4%	3,522,000	3,609,500	3,697,000	2,526,500	2,409,000	2,884,000	2,187,000	2,675,000	2,578,000	2,266,000	2,736,000	2,334,000	2,121,000	1,577,000	2,529,000	1,265,000	1,000	1,000	306,000	611,000	916,000
Gross Profit	8.2%	2,187,000	2,021,000	2,111,000	1,515,000	762,000	1,395,000	1,053,000	1,441,000	1,360,000	1,275,000	1,587,000	1,302,000	1,225,000	895,000	1,491,000	954,000	952,000	830,000	-	-	-
Operating Expenses	-10.6%	2,387,000	2,670,000	2,417,000	2,208,000	2,043,000	2,209,000	2,600,000	1,959,000	2,162,000	2,392,000	2,605,000	2,021,000	2,157,000	2,493,000	2,517,000	1,683,000	1,463,000	1,483,000	-	-	-
S&GA Expenses	-11.2%	2,142,000	2,411,000	2,124,000	1,787,500	1,743,000	1,885,000	2,177,000	1,723,000	1,718,000	1,854,000	1,999,000	1,362,000	1,544,000	1,610,000	1,950,000	1,097,000	1,069,000	1,091,000	-	-	-
R&D Expenses	1.9%	212,000	208,000	239,000	358,500	252,000	273,000	372,000	194,000	395,000	487,000	556,000	609,000	751,000	836,000	563,000	-	352,000	-	-	-	-
EBITDA Margin	-0.5%	-0.30	-0.30	-0.37	-0.43	-0.42	-0.42	-0.44	-0.42	-0.43	-0.45	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	1,000	1,000	1,000	3,000	4,000	6,000	7,000	7,000	10,000	11,000	13,000	15,000	22,000	30,000	43,000	26,000	32,000	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	37,000	7,000	14,000	21,000	1,000	-	10,000	11,000	-100,000	4,000	-	3,000	-1,795,000	2,000
EBT Margin	0%	-0.32	-0.32	-0.39	-0.45	-0.45	-0.44	-0.47	-0.44	-0.46	-0.48	-	-	-	-	-	-	-	-	-	-	-
Net Income	74.2%	-169,000	-654,000	-306,000	-848,000	-3,154,000	-1,137,000	-1,967,000	-922,500	-1,222,000	-1,126,000	-537,000	-759,000	-1,012,000	-1,657,000	-1,098,000	-725,000	-566,000	-682,000	-	-	-
Net Income Margin	8.7%	-0.10	-0.11	-0.47	-0.71	-0.71	-0.51	-0.54	-0.37	-0.37	-0.36	-0.45	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-124.0%	-672,000	-300,000	276,000	-195,000	-170,000	-1,175,000	-1,831,000	-335,000	-923,000	-117,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.8%	11,416	11,861	10,919	10,386	10,927	10,999	11,335	14,953	15,528	17,650	17,820	17,991	17,936	18,510	15,242	16,649	18,294	11,629	11,554	12,014	10,138
Current Assets	-3.3%	8,130	8,405	8,506	7,914	8,324	8,261	9,118	11,122	11,657	13,634	13,621	14,840	14,667	15,154	11,755	13,070	14,809	8,299	8,117	8,437	7,172
Cash Equivalents	-15.6%	3,633	4,307	4,622	4,060	3,836	3,634	3,940	4,179	5,421	6,973	7,350	8,278	8,163	8,249	5,155	7,046	8,962	4,166	3,855	4,318	3,608
Inventory	12.5%	2,779	2,470	2,268	2,126	2,348	3,153	3,488	4,664	4,679	4,462	4,649	5,087	4,679	5,304	5,385	4,769	3,649	2,562	2,128	2,314	2,040
Net PPE	-6.6%	142	152	88.00	98.00	107	116	128	450	384	72.00	382	303	311	295	302	296	76.00	81.00	85.00	89.00	97.00
Goodwill	-5.1%	759	800	800	759	800	800	800	800	759	759	800	800	759	800	759	759	759	759	759	759	759
Liabilities	-7.6%	3,236	3,503	2,297	1,731	2,033	2,118	1,754	2,472	2,126	2,901	2,490	3,000	2,399	2,937	3,802	4,373	4,658	3,940	4,832	5,208	4,534
Current Liabilities	-8.7%	1,929	2,113	1,828	1,197	1,415	1,412	1,551	2,111	1,748	2,390	1,823	2,170	1,408	1,325	2,379	2,765	3,108	2,428	3,116	3,292	3,110
Shareholder's Equity	-2.1%	8,180	8,358	8,622	8,655	8,894	5,592	9,581	12,481	13,402	14,749	15,330	14,991	15,537	15,573	11,440	12,276	13,636	7,689	6,722	6,806	5,604
Retained Earnings	-0.1%	-144,600	-144,406	-143,752	-143,570	-143,100	-142,831	-141,983	-138,829	-137,700	-135,725	-134,700	-133,521	-132,395	-131,858	-131,100	-130,087	-128,430	-127,332	-127,188	-126,444	-125,502
Additional Paid-In Capital	0.0%	152,745	152,754	152,364	152,215	152,021	148,413	148,275	148,040	147,781	147,346	146,883	145,378	144,801	144,296	139,410	139,243	138,953	131,934	130,830	130,169	127,974
Shares Outstanding	0.0%	10,544	10,544	10,485	10,485	10,485	10,297	10,304	10,265	10,214	10,258	9,958	9,913	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	3,289	3,279	3,260	3,242	3,054	3,054	3,054	3,053	3,051	3,052	3,046	3,040	3,014	3,009	3,003	3,000
Float	-	-	-	-	10,421	-	-	-	9,879	-	-	-	60,900	-	-	-	43,900	-	-	-	17,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-124.0%	-672	-300	598	226	276	-195	-170	-1,072	-1,797	-335	-910	-117	-55.00	-1,526	-1,817	-1,720	-1,840	364	-614	-1,329	-697
Share Based Compensation	-102.3%	-9.00	390	149	194	319	179	254	277	272	434	268	281	276	206	172	179	222	670	354	150	158
Cashflow From Investing	-	-	-	-	-	-	-	-	-103	-34.00	-	-62.00	-	-23.00	-	-13.00	-	-	-	-14.00	-	-137
Cashflow From Financing	33.3%	-2.00	-3.00	-	-2.00	-74.00	-111	-69.00	-67.00	281	-37.00	46.00	231	-3.00	4,615	-65.00	28.00	6,638	-55.00	171	2,038	-137

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NEPH Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net revenue:
Total net revenues	$ 3,522	$ 3,697
Cost of goods sold	1,335	1,586
Gross margin	2,187	2,111
Operating expenses:
Selling, general and administrative	2,142	2,124
Research and development	212	239
Depreciation and amortization	33	54
Total operating expenses	2,387	2,417
Operating loss	(200)	(306)
Other (expense) income:
Interest expense	(1)	(1)
Interest income	25	12
Other (expense) income, net	7	(11)
Total other income:	31
Net loss	$ (169)	$ (306)
Net loss per common share, basic	$ (0.02)	$ (0.03)
Net loss per common share, diluted	$ (0.02)	$ (0.03)
Weighted average common shares outstanding, basic	10,501,771	10,297,429
Weighted average common shares outstanding, diluted	10,501,771	10,297,429
Comprehensive loss	$ (169)	$ (306)
Product [Member]
Net revenue:
Total net revenues	3,506	3,662
Royalty and Other Revenues [Member]
Net revenue:
Total net revenues	$ 16	$ 35

NEPH Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,633	$ 4,307
Accounts receivable, net	1,518	1,496
Inventory	2,779	2,470
Prepaid expenses and other current assets	200	132
Total current assets	8,130	8,405
Property and equipment, net	142	152
Lease right-of-use assets	1,680	1,807
Intangible assets, net	373	381
Goodwill	759	759
License and supply agreement, net	257	271
Other assets	75	86
TOTAL ASSETS	11,416	11,861
Current liabilities:
Accounts payable	1,114	873
Accrued expenses	413	794
Current portion of lease liabilities	402	446
Total current liabilities	1,929	2,113
Lease liabilities, net of current portion	1,307	1,390
TOTAL LIABILITIES	3,236	3,503
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS’ EQUITY:
Preferred stock, $.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $.001 par value; 40,000,000 shares authorized at March 31, 2024 and December 31, 2023; 10,544,139 and 10,543,675 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10	10
Additional paid-in capital	152,745	152,754
Accumulated deficit	(144,575)	(144,406)
TOTAL STOCKHOLDERS’ EQUITY	8,180	8,358
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 11,416	$ 11,861

About Nephros Inc

Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

CEO	Mr. Robert Banks
WEBSITE	nephros.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	27

Nephros Inc Frequently Asked Questions

What is the ticker symbol for Nephros Inc? What does NEPH stand for in stocks?

NEPH is the stock ticker symbol of Nephros Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nephros Inc (NEPH)?

As of Fri May 17 2024, market cap of Nephros Inc is 25.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEPH stock?

You can check NEPH's fair value in chart for subscribers.

What is the fair value of NEPH stock?

You can check NEPH's fair value in chart for subscribers. The fair value of Nephros Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nephros Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nephros Inc a good stock to buy?

The fair value guage provides a quick view whether NEPH is over valued or under valued. Whether Nephros Inc is cheap or expensive depends on the assumptions which impact Nephros Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEPH.

What is Nephros Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NEPH's PE ratio (Price to Earnings) is -17.45 and Price to Sales (PS) ratio is 1.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nephros Inc's stock?

In the past 10 years, Nephros Inc has provided 0.213 (multiply by 100 for percentage) rate of return.